Lenalidomide plus R-CHOP (“R2-CHOP”) was subsequently offered to nd DLBCL patients in two phase II trials, in which the addition of Lenalidomide neutralized the established ABC inferiority [82,83,84], but the consecutive randomized phase III “ROBUST” trial for ABC patients only [85] and R2-Mini-CHOP for nd DLBCL patients over 80 years [86] failed by producing higher toxicity without improving overall survival [85,86]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.